Fundraising Fox

NRG Therapeutics

24 employees on LinkedIn · 12 known investors

Find your way into NRG Therapeutics

347 people in our graph share verified history with the NRG Therapeutics team — schools, employers, funds. One of them is your warm intro.

Jan Hammerunlockedknows Richard Rutter · together at University of Oxford (overlapped)
×5knows the team · via University of London
×4knows the team · via GlaxoSmithKline
×2knows the team · via University of Oxford

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's. Its team combines pharma and biotech drug discovery expertise across neurology and neuroscience.

BiotechHealthtechLongevity

Founders & leadership

NMNeil Miller
Neil MillerinCEO
RR
Richard RutterinCSORichard Rutter has over 20 years of drug discovery experience in preclinical pharmacology and biology, including previous roles as Chief Scientific Officer at Auspherix, an anti-infectives biotech. He is Chief Scientific Officer at NRG Therapeutics.
GH
Grant HawthorneinCOO
CSClaus Sundgreen
Claus SundgreeninChief Medical Officer
PTPaul Thompson
Paul ThompsoninCDO

Board

JS
Jonathan SavidgeIndependent Non Executive Chair

Investors · 12

Criteria Bio Ventures✓ verifiedBarcelona
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
SV Health Investors✓ verifiedBoston · $1M – $20M
British Business Bank✓ verifiedSheffield
M VenturesLos Angeles · $10.8M
Dementia Discovery Fundreported · 2 sourcesLondon

Also in the syndicate · 6

Merck KGaANovartisOmega FundsParkinson's UKSV Health Investors' Dementia Discovery FundleadSV Health Investors' Dementia Discovery Fund (DDF)lead

Funding

SEC filings, press & company announcements

$67M disclosed across 1 of 2 rounds · 2022–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s - Tech.eutech.eu · Sep 2025NRG Therapeutics Raises $67 Million to Advance Novel Mitochondrial-Targeting Therapy for Parkinson's and ALStrial.medpath.com · Sep 2025NRG Therapeutics raises £50m to tackle neurodegenerative disordersbusinesscloud.co.uk · Sep 2025NRG raises $67 million for a small molecule for Parkinson’s and ALScen.acs.org · Sep 2025NRG raises Series A funds for Parkinson’s and ALS therapy developmentpharmaceutical-technology.com · Nov 2022NRG Therapeutics Raises £16M in Series A Fundingfinsmes.com · Nov 2022

Frequently asked questions

What does NRG Therapeutics do?
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's. Its team combines pharma and biotech drug discovery expertise across neurology and neuroscience.
Who founded NRG Therapeutics?
NRG Therapeutics was founded by Neil Miller, Richard Rutter.
Who are NRG Therapeutics's investors?
NRG Therapeutics's investors include Criteria Bio Ventures, Novartis Venture Fund, SV Health Investors, British Business Bank, M Ventures, Dementia Discovery Fund.
How much funding has NRG Therapeutics raised?
NRG Therapeutics has disclosed $67M raised across 1 of its 2 known rounds.